Information date: 10 September 2026 — China’s foreign-investment service portal provides entry information, but remote customer discovery, cross-border contracting and local regulated delivery are not the same stage of market entry. Knowing that statement is not enough for an operating, research or compliance decision. The team must first establish who and what it applies to, how the effect reaches the real process, and which evidence would justify action.
Verified facts and scope
China’s foreign-investment service portal provides entry information, but remote customer discovery, cross-border contracting and local regulated delivery are not the same stage of market entry.
The tool records customer, product or service, contracting entity, place of delivery, data, payment, tax, import, licence, local staff, support, dispute resolution and exit trigger.
How the effect reaches operations
A remote test can validate interest with limited commitment. Once local people, inventory, regulated activities or continuous delivery are required, the operating model changes.
Calling every remote activity a harmless test may conceal tax, data or licensing exposure. Building a full entity before demand is evidenced can waste fixed cost and management time.
For “Remote China Entry Tool: Separate Market Testing from Regulated Delivery”, official rules or published findings, direct evidence from the relevant product or process, and assumptions that remain untested should be recorded separately. A broad source defines the external boundary; it does not replace batch records, protocols, contracts, labels or direct observations.
Decision
Use the lowest-commitment route that can lawfully test the next assumption; establish locally only when a verified transaction and responsibility map require it.
Implementation checklist
- Define the single customer assumption the test must confirm.
- Map contract, delivery, data and payment to entities.
- Set volume, risk and time thresholds for setup or exit.
- Assign one decision owner, one implementation owner and a dated review point for “Remote China Entry Tool: Separate Market Testing from Regulated Delivery”.
- For “Remote China Entry Tool: Separate Market Testing from Regulated Delivery”, archive the source page, access date, applicable population or entity, and internal evidence both supporting and opposing the current decision.
- When a rule, formulation, supplier, protocol or observed result changes, reopen only the affected question in “Remote China Entry Tool: Separate Market Testing from Regulated Delivery”.
Evidence and review
For “Remote China Entry Tool: Separate Market Testing from Regulated Delivery”, start with one real case rather than an abstract checklist. Record the input version, responsible owner, start time, observed result and stop condition. If the team cannot complete “Define the single customer assumption the test must confirm.” with current evidence, it should not expand the process to more products, patients, suppliers or markets. The first review should focus only on facts capable of changing the decision.
The second control follows “Map contract, delivery, data and payment to entities.”. Keep the source date, applicable population or entity, deadline, cost effect and owner in the same evidence file. A wording preference does not justify a new version. A repeated discrepancy, an unsupported health claim or a regulatory mismatch does: correct that point and hold release until the evidence is available.
After “Set volume, risk and time thresholds for setup or exit.”, compare the intended outcome with what actually happened. Apply the same success criteria to each later expansion. If only one number, date or responsibility changes, update that field and the affected conclusion instead of recreating evidence that remains valid. This keeps the decision traceable without turning review into an open-ended rewrite cycle.
Release criterion
The release test for “Remote China Entry Tool: Separate Market Testing from Regulated Delivery” is not document volume. Each material number needs a date and denominator, each action needs an owner and trigger, and each exception needs an escalation route. When the source, operating step and limit align, minor wording differences do not justify another rewrite. If the conclusion still depends on an unverified assumption, narrow the claim or pause the affected decision until direct evidence is available.
Counter-scenario and ownership
The review must also test the opposite of the expected outcome. If “A remote test can validate interest with limited commitment. Once local people, inventory, regulated activities or continuous delivery are required, the operating model changes.”, the record should already identify who detects it, who can pause the process, and who communicates with affected people or authorities. Direct, current evidence about the studied product, population or transaction takes priority when it conflicts with a broad market statement. Keep both the approval reason and the rejection reason. Later evidence should reopen only the affected question, not trigger an unsupported rewrite of findings that still hold.
Limits of the conclusion
Remote activity can still create Chinese obligations. The tool is screening, not a legal conclusion about establishment or licensing.
